NYSEAMERICAN:CVM - Cel-Sci Stock Price, Price Target & More

$1.90 +0.03 (+1.60 %)
(As of 04/19/2018 03:37 PM ET)
Previous Close$1.87
Today's Range$1.76 - $1.91
52-Week Range$1.30 - $4.00
Volume78,672 shs
Average Volume186,884 shs
Market Capitalization$25.49 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.29

About Cel-Sci (NYSEAMERICAN:CVM)

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CVM
CUSIPN/A
Phone+1-703-5069460

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5,432.69%
Return on EquityN/A
Return on Assets-110.07%

Miscellaneous

EmployeesN/A
Outstanding Shares16,500,000

How to Become a New Pot Stock Millionaire

Cel-Sci (NYSEAMERICAN:CVM) Frequently Asked Questions

What is Cel-Sci's stock symbol?

Cel-Sci trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

How were Cel-Sci's earnings last quarter?

Cel-Sci Co. (NYSEAMERICAN:CVM) issued its earnings results on Monday, February, 12th. The company reported ($0.53) earnings per share for the quarter. The business earned $0.11 million during the quarter. View Cel-Sci's Earnings History.

When is Cel-Sci's next earnings date?

Cel-Sci is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Cel-Sci.

Are investors shorting Cel-Sci?

Cel-Sci saw a drop in short interest in March. As of March 29th, there was short interest totalling 664,027 shares, a drop of 26.0% from the March 15th total of 897,860 shares. Based on an average daily trading volume, of 173,399 shares, the days-to-cover ratio is presently 3.8 days. Currently, 4.2% of the shares of the company are sold short.

Who are some of Cel-Sci's key competitors?

Who are Cel-Sci's key executives?

Cel-Sci's management team includes the folowing people:
  • Mr. Geert R. Kersten, Chief Exec., Financial & Accounting Officer, Treasurer and Director (Age 59)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 67)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 62)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research - Cellular Immunology (Age 77)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 76)

Has Cel-Sci been receiving favorable news coverage?

News stories about CVM stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cel-Sci earned a coverage optimism score of 0.23 on Accern's scale. They also gave press coverage about the company an impact score of 46.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Cel-Sci?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cel-Sci's stock price today?

One share of CVM stock can currently be purchased for approximately $1.90.

How big of a company is Cel-Sci?

Cel-Sci has a market capitalization of $25.49 million.

How can I contact Cel-Sci?

Cel-Sci's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.


MarketBeat Community Rating for Cel-Sci (CVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  124
MarketBeat's community ratings are surveys of what our community members think about Cel-Sci and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cel-Sci (NYSEAMERICAN:CVM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Cel-Sci in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Cel-Sci (NYSEAMERICAN:CVM) Consensus Price Target History

Price Target History for Cel-Sci (NYSEAMERICAN:CVM)

Cel-Sci (NYSEAMERICAN:CVM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/16/2017Dawson JamesReiterated RatingNeutralView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Cel-Sci (NYSEAMERICAN:CVM) Earnings History and Estimates Chart

Earnings by Quarter for Cel-Sci (NYSEAMERICAN:CVM)

Cel-Sci (NYSEAMERICAN CVM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
2/12/2018Q1 2018($0.53)$0.11 millionViewN/AView Earnings Details
12/29/2017Q4 2017($0.58)$0.02 millionViewN/AView Earnings Details
8/9/2017Q3 2017($0.53)$0.02 millionViewN/AView Earnings Details
5/10/2017Q2 2017($0.05)$0.02 millionViewN/AView Earnings Details
2/9/2017Q116$0.01$0.01 millionViewN/AView Earnings Details
12/14/2016Q4 2016($0.25)$0.10 millionViewN/AView Earnings Details
8/10/2016Q316($0.03)$0.13 millionViewN/AView Earnings Details
5/10/2016Q2($0.07)$0.03 millionViewN/AView Earnings Details
2/9/2016Q1 2016$0.50$0.02 millionViewN/AView Earnings Details
12/11/2015Q4 2015($2.50)($0.07) millionViewN/AView Earnings Details
8/7/2015Q3 2015($1.50)$0.39 millionViewN/AView Earnings Details
5/8/2015Q2 2015($0.12)($0.17)$0.10 million$0.20 millionViewN/AView Earnings Details
2/6/2015Q1 2015($0.09)($0.11)$0.07 million$0.14 millionViewN/AView Earnings Details
12/23/2014Q4 2014($2.25)($2.75)$0.04 million$0.07 millionViewN/AView Earnings Details
8/8/2014Q3 2014($2.75)$0.02 millionViewN/AView Earnings Details
5/13/2014Q114($0.11)($0.24)$0.02 million$0.0672 millionViewN/AView Earnings Details
2/11/2014Q413($0.11)($0.15)$510.39 million$0.11 millionViewN/AView Earnings Details
1/2/2014Q3($0.27)$0.02 millionViewN/AView Earnings Details
8/9/2013Q3 2013($5.00)($5.00)$0.10 million$0.11 millionViewN/AView Earnings Details
5/14/2013Q213($0.01)$0.07 millionViewN/AView Earnings Details
2/8/2013Q1 2013($0.01)ViewN/AView Earnings Details
12/14/2012Q4 2012($5.00)($5.00)ViewN/AView Earnings Details
8/9/2012Q3 2012($3.00)ViewN/AView Earnings Details
5/10/2012Q2 2012($10.25)ViewN/AView Earnings Details
2/9/2012Q1 2012($4.50)ViewN/AView Earnings Details
12/23/2011Q4 2011($3.25)ViewN/AView Earnings Details
8/9/2011Q3 2011($6.25)ViewN/AView Earnings Details
5/16/2011Q2 2011($9.25)ViewN/AView Earnings Details
2/10/2011Q1 2011($7.50)ViewN/AView Earnings Details
12/13/2010Q4 2010($7.50)ViewN/AView Earnings Details
8/16/2010Q3 2010($2.50)ViewN/AView Earnings Details
5/17/2010Q2 2010($7.00)ViewN/AView Earnings Details
2/16/2010Q1 2010$5.00ViewN/AView Earnings Details
1/13/2010Q4 2009($58.50)ViewN/AView Earnings Details
8/14/2009Q3 2009($12.75)ViewN/AView Earnings Details
5/15/2009Q2 2009($4.00)ViewN/AView Earnings Details
8/19/2008Q3 2008$5.00ViewN/AView Earnings Details
5/16/2008Q2 2008($7.75)ViewN/AView Earnings Details
2/14/2008Q1 2008($5.00)ViewN/AView Earnings Details
1/14/2008Q4 2007($2.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cel-Sci (NYSEAMERICAN:CVM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cel-Sci (NYSEAMERICAN CVM) Insider Trading and Institutional Ownership History

Insider Trading History for Cel-Sci (NYSEAMERICAN:CVM)

Cel-Sci (NYSEAMERICAN CVM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Peter R YoungDirectorBuy6,500$1.80$11,700.003,691View SEC Filing  
1/22/2018Eyal TalorInsiderSell8,192$2.06$16,875.52117,698View SEC Filing  
1/16/2018Eyal TalorInsiderSell1,808$2.15$3,887.20121,156View SEC Filing  
1/12/2018Eyal TalorInsiderSell101$2.15$217.15121,156View SEC Filing  
10/17/2017Vicente Benjamin AsuncionDirectorSell160,000$0.39$62,400.00
8/25/2017Eyal TalorInsiderSell769$1.91$1,468.79118,543View SEC Filing  
8/16/2017Eyal TalorInsiderSell14,019$2.61$36,589.59131,312View SEC Filing  
10/13/2014Geert R KerstenCEOBuy14,999$0.77$11,549.23View SEC Filing  
12/30/2013Geert R KerstenCEOBuy300,000$0.60$180,000.00View SEC Filing  
10/9/2013Geert R KerstenInsiderBuy8,400$0.79$6,636.00View SEC Filing  
6/19/2013Peter R YoungDirectorBuy25,000$0.24$6,000.00View SEC Filing  
6/14/2013Geert R KerstenInsiderBuy145,120$0.24$34,828.80View SEC Filing  
5/20/2013Geert R KerstenCEOBuy40,000$0.25$10,000.00View SEC Filing  
5/2/2013Geert R KerstenCEOBuy118,700$0.27$32,049.00View SEC Filing  
3/27/2013Peter R YoungDirectorBuy25,000$0.23$5,750.00View SEC Filing  
3/26/2013Geert R KerstenCEOBuy348,125$0.21$73,106.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cel-Sci (NYSEAMERICAN CVM) News Headlines

Source:
DateHeadline
Peter R. Young Acquires 6,500 Shares of Cel-Sci Co. (CVM) StockPeter R. Young Acquires 6,500 Shares of Cel-Sci Co. (CVM) Stock
www.americanbankingnews.com - April 17 at 1:23 PM
Should You Worry About CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Pay?Should You Worry About CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Pay?
finance.yahoo.com - April 11 at 3:58 PM
Cel-Sci Co. (CVM) Sees Significant Decrease in Short InterestCel-Sci Co. (CVM) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 11 at 2:04 AM
Cel-Sci (CVM) Upgraded to "Sell" at ValuEngineCel-Sci (CVM) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 10 at 5:02 PM
CEL-SCI Corporation to Present at The MicroCap ConferenceCEL-SCI Corporation to Present at The MicroCap Conference
finance.yahoo.com - April 9 at 10:22 AM
Cel-Sci (CVM) Receives "Neutral" Rating from Dawson JamesCel-Sci (CVM) Receives "Neutral" Rating from Dawson James
www.americanbankingnews.com - April 6 at 4:46 PM
CEL-SCI Corporation Issues Letter to ShareholdersCEL-SCI Corporation Issues Letter to Shareholders
finance.yahoo.com - April 4 at 5:40 PM
Form 4 CEL SCI CORP For: Mar 30 Filed by: PRICHEP PATRICIA BForm 4 CEL SCI CORP For: Mar 30 Filed by: PRICHEP PATRICIA B
www.streetinsider.com - April 3 at 10:27 AM
Form 4 CEL SCI CORP For: Mar 30 Filed by: ZIMMERMAN DANIEL HForm 4 CEL SCI CORP For: Mar 30 Filed by: ZIMMERMAN DANIEL H
www.streetinsider.com - April 3 at 10:27 AM
Multikine Immunotherapy: Cel-Sci Is Weathering The StormMultikine Immunotherapy: Cel-Sci Is Weathering The Storm
seekingalpha.com - April 2 at 3:59 PM
CEL-SCI Co. (CVM) Short Interest Down 7.0% in MarchCEL-SCI Co. (CVM) Short Interest Down 7.0% in March
www.americanbankingnews.com - March 27 at 1:02 AM
With A -133.58% Earnings Drop, Is CEL-SCI Corporation’s (NYSEMKT:CVM) A Concern?With A -133.58% Earnings Drop, Is CEL-SCI Corporation’s (NYSEMKT:CVM) A Concern?
finance.yahoo.com - March 14 at 11:25 AM
CEL-SCI Co. (CVM) Short Interest UpdateCEL-SCI Co. (CVM) Short Interest Update
www.americanbankingnews.com - March 10 at 3:15 AM
Who Are CEL-SCI Corporation’s (NYSEMKT:CVM) Major Shareholders?Who Are CEL-SCI Corporation’s (NYSEMKT:CVM) Major Shareholders?
finance.yahoo.com - February 28 at 10:04 AM
Short Interest in CEL-SCI Co. (CVM) Increases By 56.3%Short Interest in CEL-SCI Co. (CVM) Increases By 56.3%
www.americanbankingnews.com - February 27 at 6:00 PM
CEL-SCI (CVM) Releases  Earnings ResultsCEL-SCI (CVM) Releases Earnings Results
www.americanbankingnews.com - February 13 at 10:50 AM
CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial ResultsCEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results
finance.yahoo.com - February 13 at 8:42 AM
Cel-Sci reports 1Q lossCel-Sci reports 1Q loss
finance.yahoo.com - February 13 at 8:42 AM
CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor ConferenceCEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 12 at 5:02 PM
CEL-SCI Co. (CVM) Sees Large Decrease in Short InterestCEL-SCI Co. (CVM) Sees Large Decrease in Short Interest
www.americanbankingnews.com - February 9 at 6:56 PM
CEL-SCI to Present at 2018 BIO CEO & Investor ConferenceCEL-SCI to Present at 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 4:49 PM
CEL-SCI Corp (CVM) Announces US Patent Office Allows New Patent For LEAPS Vaccine Platform Technology - StreetInsider.comCEL-SCI Corp (CVM) Announces US Patent Office Allows New Patent For LEAPS Vaccine Platform Technology - StreetInsider.com
www.streetinsider.com - January 31 at 8:51 AM
U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform TechnologyU.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology
finance.yahoo.com - January 30 at 4:55 PM
Short Interest in CEL-SCI Co. (CVM) Grows By 48.9%Short Interest in CEL-SCI Co. (CVM) Grows By 48.9%
www.americanbankingnews.com - January 24 at 6:10 PM
CEL-SCI Co. (CVM) Insider Sells $16,875.52 in StockCEL-SCI Co. (CVM) Insider Sells $16,875.52 in Stock
www.americanbankingnews.com - January 22 at 7:04 PM
Active-Investors: Wired News - Pluristems PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed ArticleActive-Investors: Wired News - Pluristem's PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article
www.finanznachrichten.de - January 17 at 8:27 AM
Wired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed ArticleWired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article
finance.yahoo.com - January 17 at 8:26 AM
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis - Business Wire (press release)CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis - Business Wire (press release)
www.businesswire.com - January 8 at 11:51 AM
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid ArthritisCEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
finance.yahoo.com - January 8 at 9:50 AM
CEL-SCI Issues Letter to Shareholders - Business Wire (press release)CEL-SCI Issues Letter to Shareholders - Business Wire (press release)
www.businesswire.com - January 4 at 8:47 AM
CEL-SCI Issues Letter to ShareholdersCEL-SCI Issues Letter to Shareholders
finance.yahoo.com - January 3 at 8:46 AM
CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate DevelopmentsCEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments
finance.yahoo.com - December 29 at 5:09 PM
What Is The Future Prospect For Healthcare And CEL-SCI Corporation (NYSEMKT:CVM)?What Is The Future Prospect For Healthcare And CEL-SCI Corporation (NYSEMKT:CVM)?
finance.yahoo.com - December 29 at 10:08 AM
What Did CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Take Home Last Year?What Did CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Take Home Last Year?
finance.yahoo.com - December 21 at 8:45 AM
CEL-SCI Corp (CVM) Appoints Robert Watson to Board - StreetInsider.comCEL-SCI Corp (CVM) Appoints Robert Watson to Board - StreetInsider.com
www.streetinsider.com - December 19 at 5:13 PM
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study - Business Wire (press release)CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study - Business Wire (press release)
www.businesswire.com - December 12 at 10:02 AM
Short Interest in CEL-SCI Co. (CVM) Drops By 11.8%Short Interest in CEL-SCI Co. (CVM) Drops By 11.8%
www.americanbankingnews.com - December 12 at 2:26 AM
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer StudyCEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
finance.yahoo.com - December 11 at 5:26 PM
CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head ... - Business Wire (press release)CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head ... - Business Wire (press release)
www.businesswire.com - December 9 at 8:44 AM
CEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study - StreetInsider.comCEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study - StreetInsider.com
www.streetinsider.com - December 8 at 9:36 AM
CEL-SCI (CVM) Scheduled to Post Quarterly Earnings on TuesdayCEL-SCI (CVM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - December 5 at 1:44 AM
CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend?CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend?
finance.yahoo.com - November 30 at 8:54 AM
Short Interest in CEL-SCI Co. (CVM) Declines By 10.2%Short Interest in CEL-SCI Co. (CVM) Declines By 10.2%
www.americanbankingnews.com - November 27 at 9:56 PM
Flaherty Financial Newsletter Spotlights "CEL-SCI Corporations Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60Flaherty Financial Newsletter Spotlights "CEL-SCI Corporation's Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60
finance.yahoo.com - November 14 at 6:05 PM
CEL-SCI Announces Update on Arbitration against Former Clinical Research OrganizationCEL-SCI Announces Update on Arbitration against Former Clinical Research Organization
finance.yahoo.com - November 13 at 12:36 PM

SEC Filings

Cel-Sci (NYSEAMERICAN:CVM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cel-Sci (NYSEAMERICAN:CVM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cel-Sci (NYSEAMERICAN CVM) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.